Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AbbVie

2 Dividend Stocks You Can’t Miss in 2025

These companies are well-established with a solid track record of earnings growth and can cushion your portfolio with stability.

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

3 Highest-Yielding Dividend Kings To Buy Today

3 Highest-Yielding Dividend Kings To Buy Today

Start your New Year early by exploring high-yield Dividend Kings with decades of growth, top analyst ratings, and attractive yields for long-term investors.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Parkinson's disease symptoms reduced by drug in late-stage trial

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose.

Check Out What Whales Are Doing With ABBV

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 10 unusual trades.

Is AbbVie Stock Underperforming the Dow?

AbbVie has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

Check Out What Whales Are Doing With ABBV

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.

inkl

Read news from The Economist, FT, and more,
with one subscription

Pharma giant taken to court after breast implant recall

Pharma giant taken to court after breast implant recall

Patients allegedly exposed to a higher cancer risk from 'defective' breast implants that have now been recalled are suing a pharmaceutical firm seeking damages.

Don't Miss the Buying Opportunity in This Dividend King, Says Analyst

Don't Miss the Buying Opportunity in This Dividend King, Says Analyst

Leerink believes the recent selloff has made valuations attractive.

Spotlight on AbbVie: Analyzing the Surge in Options Activity

Spotlight on AbbVie: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:ABBV).

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.

4 Analysts Assess Enanta Pharma: What You Need To Know

4 Analysts Assess Enanta Pharma: What You Need To Know

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

Market Whales and Their Recent Bets on ABBV Options

Market Whales and Their Recent Bets on ABBV Options

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.

3 Oversold Dividend Aristocrats Ready To Explode in 2025

3 Oversold Dividend Aristocrats Ready To Explode in 2025

These three companies all have one thing in common: they are all on sale.

Get all your
news in one place.

100's of premium titles.
One news app.

Stocks Settle Mostly Higher on President-Elect Trump’s Pro-Growth Promises

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%. Stocks on Monday settled mixed, with the S&P 500 and the Dow Jones Industrials...

Is This Dividend King a Buy After a Strong Q3 Report?

This might be the perfect opportunity to buy this growth and income stock at a discount.

Stocks Rally on Optimism in President-Elect Trump’s Policies

The S&P 500 Index ($SPX ) (SPY ) today is up +0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.94%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.07%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

S&P 500 and Dow Jones Industrials at Record Highs as the Post-Election Rally Continues

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.19%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

Get all your
news in one place.

100's of premium titles.
One news app.

Are Wall Street Analysts Bullish on AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

HR leaders share how they're putting people first in an ever-changing workplace

HR professionals are navigating RTO, AI, cultural changes, and divisive virtual cultural issues.

3 Undervalued Dividend Aristocrats Poised for Explosive Gains in 2025

Hunting for value? These three Dividend Aristocrats look cheap by today's valuations.

AbbVie's Q3 2024 Earnings: What to Expect

With AbbVie gearing up to release its third-quarter earnings later this month, analysts expect a marginal decline in earnings.

3 Highest-yielding Dividend Kings for Maximum Income and Stability

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

The Conversation

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

1 … 4 5 6 7

People

199,150 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

391,773 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play